Objective To explore the effects of carrilizumab(SHR-1210)combined with chemotherapy on the thera-peutic efficacy and intratumoral microbiota in patients with advanced gastric cancer.Methods In total,92 patients with ad-vanced gastric cancer treated from April 2020 to May 2021 were selected and divided into research group and control group ac-cording to different treatment methods.The research group received SHR-1210 combined chemotherapy,and the control group received chemotherapy.The therapeutic effect,the levels of serum carcinoembryonic antigen(CEA)and cancer antigen 19-9(CA19-9)before and after treatment,detection rate of intratumoral microbiota after treatment,natural killer(NK)cells and T lymphocyte subsets after treatment,as well as adverse reactions,2-year progression-free survival(PFS)and overall survival(OS)were compared between the two groups.Results After treatment,the total effective rate was 89.1%(41/46)in the research group,which was higher than that[56.5%(26/46)]in the control group(P<0.01).After treatment,the levels of serum CEA,CA19-9,detection rate of intratumoral microbiome,CD8 + and NK cells in the research group were lower than those in the control group(P<0.05,P<0.01).After treatment,the levels of CD4 + and CD4 +/CD8 + in the research group were higher than those in the control group,and the 2-year PFS rate and OS rate were higher than those in the control group(P<0.05,P<0.01).The total incidence of adverse reactions in the research group was lower than that in the control group(P<0.01).Conclusion SHR-1210 combined with chemotherapy can reduce the levels of serum CEA and CA19-9 in patients with advanced gastric cancer,reduce the intratumoral microbiota,greatly improve the safety of treatment,and improve the prognosis,showing significant effects.
维普
万方数据